Skip to main content

Larotrectinib: A Targeted Therapy for Solid Tumors.

Publication ,  Journal Article
Mota-George, G; Schneider, SM
Published in: Clinical journal of oncology nursing
April 2021

Although neurotrophic tyrosine receptor kinase (NTRK) gene fusions are not common in most cancers, they are present in more than 90% of some rare tumors. The U.S. Food and Drug Administration has approved larotrectinib for patients with NTRK gene fusion-positive cancers that meet certain criteria. With ongoing advancements in tumor sequencing, it is anticipated that cancer treatment will be determined by genetic variants rather than by cancer type in the future.This article provides an overview of larotrectinib, a targeted therapy.This article reviews clinical trial results and highlights implications for oncology nurses caring for patients taking larotrectinib.Larotrectinib is an effective treatment option for some patients with NTRK gene fusion-positive cancers. Oncology nurses are key to educating patients on dosing, administration, side effects, and precautions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clinical journal of oncology nursing

DOI

EISSN

1538-067X

ISSN

1092-1095

Publication Date

April 2021

Volume

25

Issue

2

Start / End Page

181 / 187

Related Subject Headings

  • Pyrimidines
  • Pyrazoles
  • Protein Kinase Inhibitors
  • Neoplasms
  • Humans
  • 4205 Nursing
  • 3211 Oncology and carcinogenesis
  • 1110 Nursing
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mota-George, G., & Schneider, S. M. (2021). Larotrectinib: A Targeted Therapy for Solid Tumors. Clinical Journal of Oncology Nursing, 25(2), 181–187. https://doi.org/10.1188/21.cjon.181-187
Mota-George, Gabriela, and Susan M. Schneider. “Larotrectinib: A Targeted Therapy for Solid Tumors.Clinical Journal of Oncology Nursing 25, no. 2 (April 2021): 181–87. https://doi.org/10.1188/21.cjon.181-187.
Mota-George G, Schneider SM. Larotrectinib: A Targeted Therapy for Solid Tumors. Clinical journal of oncology nursing. 2021 Apr;25(2):181–7.
Mota-George, Gabriela, and Susan M. Schneider. “Larotrectinib: A Targeted Therapy for Solid Tumors.Clinical Journal of Oncology Nursing, vol. 25, no. 2, Apr. 2021, pp. 181–87. Epmc, doi:10.1188/21.cjon.181-187.
Mota-George G, Schneider SM. Larotrectinib: A Targeted Therapy for Solid Tumors. Clinical journal of oncology nursing. 2021 Apr;25(2):181–187.

Published In

Clinical journal of oncology nursing

DOI

EISSN

1538-067X

ISSN

1092-1095

Publication Date

April 2021

Volume

25

Issue

2

Start / End Page

181 / 187

Related Subject Headings

  • Pyrimidines
  • Pyrazoles
  • Protein Kinase Inhibitors
  • Neoplasms
  • Humans
  • 4205 Nursing
  • 3211 Oncology and carcinogenesis
  • 1110 Nursing